<DOC>
	<DOCNO>NCT02394119</DOCNO>
	<brief_summary>Open-label , two-parallel-arm , control randomized clinical trial test superiority Ofatumumab Rituximab maintain steroid- calcineurin-inhibitor-free disease remission SD-INS . Eligible participant enter 1-month run-in period , instruction urine collection dipstick reading carefully review , compliance assess , therapy RAS inhibitor withdraw , hypertensive child replace anti-hypertensive drug . After run-in period , child randomize either intervention arm ( Ofatumumab ) comparator arm ( Rituximab ) . After infusion intervention comparator , steroid maintain initial dose 30 day taper 0.3 mg/kg per week complete withdrawal . One week steroid withdrawal calcineurin inhibitor decrease 50 % withdrawn within 2 additional week . All patient follow 24 month . In case relapse study ( see outcome section definition ) patient treat 60 mg/m2of prednisone p.o . order achieve remission . At remission , patient treat another infusion either Oftumumab Rituximab , accord initial randomization . After infusion intervention comparator , steroid maintain initial dose 30 day taper 0.3 mg/kg per week complete withdrawal . One week steroid withdrawal calcineurin-inhibitors decrease 50 % withdrawn within 2 additional week . This strategy repeat treat full relapse study .</brief_summary>
	<brief_title>Ofatumumab Versus Rituximab Children With Steroid Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>To eligible inclusion study , participant fulfill follow criterion : To complete disease remission Drug dependence : remission maintain steroid CNI steroid dependence define two consecutive relapse corticosteroid therapy within 14 day cease therapy . CNI ( cyclosporine/tacrolimus ) dependence define presence relapse discontinuation . Ability provide consent assent : parents'/guardian 's write informed consent , child 's assent give studyrelated procedure part subject 's normal medical care , understand consent may withdraw subject time without prejudice future medical care . Age 2 18 year Children exclude follow criterion apply : Positivity autoimmunity test ( ANA , nDNA , ANCA ) Reduction C3 level . eGFR &lt; 90/ml/min/1,73 m2 valuate accord revise Bedside Schwartz Formula patient 2 17 year CKDEPI Creatinine 2009 Equation 18 year old patient . Pregnancy Neoplasm Infections : previous actual HBV ( HBeAb positivity ) HCV infection CD20 B lymphocytes count &lt; 2,5 % Treatment Rituximab cyclophosphamide last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>